Shire plc, of Dublin, reported a $387 million net loss for the third quarter and lowered its full-year guidance, citing an increase in integration costs related to its $32 billion buyout of Baxalta Inc., costs related to licensing SHP647 (formerly Pfizer Inc.’s PF-547659) and reorganization costs associated with the planned closure of a facility in its Los Angeles manufacturing site.